La Jolla Pharmaceutical Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" La Jolla Pharmaceutical stock.
View analyst ratings for La Jolla Pharmaceutical or view top-rated stocks.

Wall Street analysts have given La Jolla Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but La Jolla Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.11. The biopharmaceutical company earned $9.07 million during the quarter.
View La Jolla Pharmaceutical's earnings history.

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC shares have increased by 2.3% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19.

1 brokers have issued 12-month price objectives for La Jolla Pharmaceutical's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate La Jolla Pharmaceutical's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical or view top-rated stocks among Wall Street analysts.

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to La Jolla Pharmaceutical include Gritstone Oncology (GRTS), Harpoon Therapeutics (HARP), Fusion Pharmaceuticals (FUSN), Opthea (OPT), AVROBIO (AVRO), Cellular Biomedicine Group (CBMG), Freeline Therapeutics (FRLN), Cardiff Oncology (CRDF), Codiak BioSciences (CDAK), Innate Pharma (IPHYF), SQZ Biotechnologies (SQZ), Aptose Biosciences (APTO), Outlook Therapeutics (OTLK), Innate Pharma (IPHA) and Surface Oncology (SURF).
View all of LJPC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

La Jolla Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.40%), Alyeska Investment Group L.P. (1.96%), Alyeska Investment Group L.P. (1.96%), Northern Trust Corp (0.91%), Nuveen Asset Management LLC (0.58%) and First Midwest Bank Trust Division (0.57%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, David A Ramsay and Kevin C Tang.
View institutional ownership trends for La Jolla Pharmaceutical.

LJPC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Wells Fargo & Company MN, RMR Wealth Builders, Signaturefd LLC, JPMorgan Chase & Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for La Jolla Pharmaceutical or view top insider-selling stocks.

LJPC stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Renaissance Technologies LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., BlackRock Inc., Virtu Financial LLC, Nuveen Asset Management LLC, and Walleye Capital LLC. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, David A Ramsay, and Kevin C Tang.
View insider buying and selling activity for La Jolla Pharmaceutical or or view top insider-buying stocks.

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LJPC stock can currently be purchased for approximately $4.92.

La Jolla Pharmaceutical has a market capitalization of $134.71 million and generates $23.05 million in revenue each year. The biopharmaceutical company earns $-116,510,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

La Jolla Pharmaceutical employs 90 workers across the globe.

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

La Jolla Pharmaceutical is headquartered at 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121.

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]